The optimization of prolonged release matrix tablets with betahistine dihydrochloride - part I

Farmacia

Volumn 59, Issue 2, 2011, Pages 209-215

  Cazacincu, Radu ^a   Lupuliasa, Dumitru ^b   Mourad, Ali Hamze ^b  

^a OVIDIUS UNIVERSITY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Betahistine dihydrochloride; Hydroxypropyl methylcellulose (HPMC); Prolonged release matrix tablets

Indexed keywords

AEROSIL; BETAHISTINE; CITRIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; SILICON DIOXIDE; TALC; UNCLASSIFIED DRUG; VIVAPUR 102;

ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG SOLUBILITY; HYDROPHILICITY; MATRIX TABLET; TABLET COMPRESSION; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS; VISCOSITY;

EID: 79955785838     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Popovici I, Lupuleasa D, Tehnologie Farmaceutica Vol 3, Editura Polirom, 2009, 627-640
2. Tiwari S.B., Rajabi-Siahboomi A.R., Modulation of drug release from hydrophilic matrices, Pharmaceutical Tehnology Europe, September 2008, 24-31
3. Nelson E., Sallee F, Treatment methods employing histamine H3 Receptor antagonists, including betahistine, World Intellectual Property Organization, 2007
4. Lacour M., Sterkers O., Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action, CNS Drugs, 2001, 15(11): 853-870
5. Gater P.R., Webber S.E., Gui G.P., Jordan C.C., Hayes N.A., Ashford J.J., Foreman J.C., Some studies of the action of betahistine at H1 and H2 receptors for histamine, Agents and actions, 1986, 18(3-4): 342-350
6. Kantor I., Jurkiewicz D., Assessment of betahistine dihydrochloride effectiveness in the treatment of vertigo of a different aetiology based on videonystamography test results, Polski merkuriuys lekarski: organ Polskiego Towarzystwa Lekarskiego, 2006, 20(117): 318-321
7. Dutia M.B., Betahistine, vestibular function and compensation: in vitro studies of vestibular function and plasticity, Acta otolaryngologica, 2000, 544: 11-14
8. Dutia M.B. European Pharmacopoeia 6.0. Edition 2008: 278-279
9. Iovanov R., Tomuta I., Leucuta S., Influence of some formulation factors on the release of felodipine from extended release hydrophilic matrix tablets Farmacia, 2009, 57, 5, 582-589
10. Ochiuz L., Stoleriu I., Moscalu M., Popa G., Spac A., Popovici I., Investigations on the in vitro release mechanism of sodium alendronate from hydrofilic matrix tablets Farmacia, 2010, 58, 6, 795-805